PHOENIX -- (BUSINESS WIRE) -- Creative Medical Health, Inc. (CMH) announced today initiation of efforts to recruit a preeminent U.S. urologist as principal investigator to run a Phase I/II study under FDA jurisdiction assessing efficacy of its patented method of treating erectile dysfunction.
Creative Medical Health, Inc. owns U.S. patent #8,372,797, titled “Treatment of Erectile Dysfunction by Stem Cell Therapy,” which covers the use of various stem cells for treatment of patients who are resistant to Viagra, Cialis and Levitra. In contrast to pharmaceutical agents, the treatment developed by Creative Medical Health, Inc. involves regenerating the blood vessels and smooth muscle of the penis, thus offering the possibility of permanent regeneration, not a temporary remedy.
The medical procedure involves extracting stem cells from the patient’s own bone marrow, processing them and subsequent administration into the penis. A peer-reviewed study describing the first patient treated with this procedure may be found at http://www.translational-medicine.com/content/pdf/1479-5876-11-139.pdf.
“There are approximately 18 million patients with erectile dysfunction in the USA. Of these, 30% are resistant to pharmaceutical interventions, which represents approximately 5.4 million potential patients that could benefit from our approach,” stated Timothy Warbington, CEO of Creative Medical Health, Inc. “Given that this patient group has limited alternatives besides costly implants and injections before intercourse, which can be associated with horrific side effects, we believe it is our responsibility to accelerate development of this program in a timely manner.”
The use of bone marrow stem cells is currently part of medical practice in bone marrow transplantation, and is currently in advanced clinical trials for conditions including heart failure, peripheral artery disease and stroke. Creative Medical Health, Inc. is the first to patent and subsequently clinically validate the feasibility of applying this form of stem cell therapy to urological conditions.
Investigators interested in collaborating with Creative Medical Health, Inc. should contact Timothy Warbington at CEO@creativemedicalhealth.com.
About Creative Medical Health Inc:
CREATIVE MEDICAL HEALTH, INC. and its wholly owned subsidiaries, in collaboration with leading U.S. universities, physicians and scientists, have developed and tested our patented cutting-edge BIONUTRACEUTICAL(TM) products, stem cell related blood testing services and treatment of various medical conditions with stem cell technology. Our area of concentration is the scientific and evidence-based approach to the approximately $30 billion per year complementary and alternative medicine market in the United States and $250 billion worldwide market. For more information about Creative Medical Health go to www.creativemedicalhealth.com.
The statements and products have not been evaluated or approved by the FDA. They are not intended to diagnose, treat, cure or prevent any disease or condition.